Clinuvel Pharmaceuticals (ASX:CUV) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
85 GF Score
Price A$10.20
GF Value A$17.70
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Clinuvel Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASX:CUV vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


ASX:CUV
85GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.20 is trading 42.4% below its estimated GF Value™ of A$17.70. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: A$17.70 vs. price of A$10.20 (42.4% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score

Get the complete analysis for ASX:CUV

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.20
Price
A$17.70
GF Value